Marketing: Page 50
-
Deep Dive
5 Trends affecting gene therapy development
A pricing conundrum and ethical decisions are clouding an already hazy path to market for many gene therapy drugs and providers.
By Jacob Bell • June 12, 2017 -
Lilly preps galcanezumab for 2017 filing
The migraine drug showed strong efficacy across a trio of late-stage studies, and its submission to the FDA should come later this year.
By Jacob Bell • June 10, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Strokes on the rise, but NOACs not filling the gap
New oral anticoagulants have become the new standard of care for stroke treatment, but the drugs have not lived up to expectation.
By Barbara Boughton • June 9, 2017 -
ADA preview: 5 things to watch in diabetes
Cardiovascular outcomes data, insulin pricing and technology are just a few of the things acting as major change agents in diabetes.
By Lisa LaMotta • June 9, 2017 -
AMA to vote on resolution calling for inclusion of drug prices in DTC ads
The American Medical Association has been outspoken on DTC advertising before, calling for a ban in 2015 on such marketing for pharmaceutical products.
By Barbara Boughton • June 7, 2017 -
Remodeled drug pricing bill likely to get Nevada Gov.'s signature
The new legislation requires drug manufacturers and PBMs to provide information to the state about price hikes for essential diabetes medicines.
By Jacob Bell • June 7, 2017 -
AbbVie, Novo, Takeda have best reputations in pharma, new study finds
Perceptions were mostly positive about the industry's commitment to financials and effective products, but not as much when it came to ethics.
By Jacob Bell • June 2, 2017 -
Opinion
The perils of building clinical trials on a shaky foundation
With the odds stacked against clinical trial success, drug developers need all the tools in their arsenal to make sure they recruit patients quickly and design trials effectively.
By Craig Morgan • June 1, 2017 -
Report: Oncology costs increasing faster than before
A QuintilesIMS study highlights the increased efficiency of the regulatory process for cancer drugs, a welcome development but one that has buoyed spending.
By Lisa LaMotta • June 1, 2017 -
US may have overpaid $1.3B for Mylan's EpiPen, HHS watchdog says
Mylan has yet to finalize a settlement with the DOJ to resolve allegations it misclassified EpiPen as generic and therefore paid lower rebates.
By Ned Pagliarulo • June 1, 2017 -
Lilly's Strattera faces first wave of generic competition
The FDA approved copycat versions of the big drugmaker's ADHD medication on Tuesday, which should cause a sizable hit to its 2017 revenues.
By Jacob Bell • May 31, 2017 -
Novartis' Zykadia gets 1st-line nod in ALK+ lung cancer
The expanded approval cements Novartis’ position in the market for treatment of ALK-positive NSCLC patients.
By Barbara Boughton • May 31, 2017 -
Drug rebates may shift costs to Medicare, study finds
While industry argues rebates lower drug and premium costs, a new paper suggests the practice leads to higher out-of-pocket spending and a heavier burden on Medicare.
By Ned Pagliarulo • May 31, 2017 -
AstraZeneca taps outcomes deals to boost CV, diabetes meds
Two agreements with Harvard Pilgrim for Brilinta and Bydureon will link drug cost to certain patient outcomes — the most recent examples of value-based deals.
By Ned Pagliarulo • May 31, 2017 -
Merck, UnitedHealth explore improving value-based contracts
The big pharma and insurer are working on a multiyear project aimed at better understanding and optimizing pay-for-performance deals.
By Jacob Bell • May 26, 2017 -
Deep Dive
Industry Pulse: Aging blockbusters tax bottom lines
A number of pharmas face declining sales and tougher competition to once-dominant brands. Here are eight charts showing which companies are most at risk.
By Ned Pagliarulo • May 26, 2017 -
Roche looks into PML report for Ocrevus patient
A case of the deadly brain disease has surfaced in a patient who took the new MS drug, but also has a history of taking Biogen's Tysabri.
By Lisa LaMotta • May 25, 2017 -
Merck may face financial fine for anti-competitive pricing
A U.K. regulator has issued a provisional ruling against Merck, Sharp & Dohme for engaging in anti-competitive pricing to defend Remicade sales from biosimilar competition.
By Barbara Boughton • May 24, 2017 -
Merck's Keytruda gets first nod in genetically-defective tumors
The anti-PD-1 drug locked down another indication, this time for solid tumors that have defective genetic code.
By Jacob Bell • May 24, 2017 -
AstraZeneca offloads more non-core assets
The British drugmaker has worked to trim its portfolio, selling off older drugs to help offset revenue declines from key products.
By Suzanne Elvidge • May 23, 2017 -
EMA recommends 11 drugs for approval in May meeting
The list of CHMP-backed new treatments included Sanofi's biosimilar Humalog, LEO Pharma's brodalumab and Gedeon Richter's cariprazine.
By Jacob Bell • May 22, 2017 -
Sponsored by ZS Associates
Patient centricity is important, but customer centricity is imperative
It's time for pharma companies to reinvent the way they go to market and find new ways to connect with physicians, provider organizations, payers and patients.
May 18, 2017 -
Vertex bumps sales guidance on new Kalydeco approval
Approval will expand the market for Kalydeco by approximately 900 people who have one of 23 specific mutations to a key gene involved in cystic fibrosis.
By Suzanne Elvidge • May 18, 2017 -
Akebia partners with Vifor to expand distribution of anemia drug
The Cambridge biotech announced a licensing deal that will give it exclusive access to sell vadadustat to one of the largest U.S. dialysis providers, pending approval.
By Barbara Boughton • May 17, 2017 -
FDA
FDA warns of higher amputation risk for J&J's Invokana
Results from two clinical studies showed the risk of amputation was roughly double for the SGLT-2 inhibitor compared to placebo.
By Ned Pagliarulo • May 17, 2017
Previous
